Washington is currently home to 1780 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437
Recruiting
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Capital Clin Res Ctr,LLC, Olympia, Washington
Conditions: Obesity
Register for Updates
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
NCT06111586
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study that consists of 2 parts. In Part A the safety of the highest dose-level of frexalimab in adults (age range 18-35 y.o.) will be established. In Part B, a dose-finding study (adolescents and young adults, 12-21 y.o.) evaluating the safety and efficacy of 3 age-adjusted dose-levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. The purpose of this study is to determine safety a... Read More
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
06/17/2024
Locations: Benaroya Research Institute at Virginia Mason Site Number : 8400016, Seattle, Washington
Conditions: Type 1 Diabetes Mellitus
Register for Updates
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632
Recruiting
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: are 18 years of age or older; are hormone receptor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Advanced or Metastatic Breast Cancer
Register for Updates
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
NCT06074562
Recruiting
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
NCT06039189
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Frontier Derm Partners CRO, LLC, Mill Creek, Washington
Conditions: Moderate Plaque Psoriasis
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Spokane, Washington
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435
Recruiting
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Vista Oncology Inc PS, Olympia, Washington
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231
Recruiting
This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck squamous cell cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. Participants must have tumors that have a marker called HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). DV is a type... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
Register for Updates
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
NCT05969223
Recruiting
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe sca... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: North Sound Dermatology /ID# 264565, Mill Creek, Washington
Conditions: Genital Psoriasis, Scalp Psoriasis
Register for Updates
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Obesity, Overweight, Osteo Arthritis Knee
Register for Updates
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079
Recruiting
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
Register for Updates
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066
Recruiting
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Obesity, Overweight, Knee Pain Chronic, Knee Osteoarthritis, Obstructive Sleep Apnea
Register for Updates